The epidemiology of Parkinson's disease: risk factors and prevention

The Lancet Neurology

Volumn 15, Issue 12, 2016, Pages 1257-1272

  Ascherio, Alberto ^a,b,c   Schwarzschild, Michael A ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; FAT; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHAMPHETAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PESTICIDE; TRACE ELEMENT; URATE; VITAMIN;

ALCOHOL CONSUMPTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COFFEE; DAIRY PRODUCT; DIABETES MELLITUS; DIETARY INTAKE; DISEASE COURSE; HUMAN; HYPERTENSION; MACRONUTRIENT; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; TEA; TRAUMATIC BRAIN INJURY;

HUMANS; PARKINSON DISEASE;

EID: 84992198065     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30230-7     Document Type: Review

References (238)

1. 1 Singleton, AB, Farrer, MJ, Bonifati, V, The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 28 (2013), 14–23.
2. 2 Kalia, LV, Lang, AE, Parkinson's disease. Lancet 386 (2015), 896–912.
3. 3 Klein, C, Westenberger, A, Genetics of Parkinson's disease. Cold Spring Harb Perspect Med, 2, 2012, a008888.
4. 4 Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002), 861–870.
5. 5 Savica, R, Rocca, WA, Ahlskog, JE, When does Parkinson disease start?. Arch Neurol 67 (2010), 798–801.
6. 6 Park, M, Ross, GW, Petrovitch, H, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64 (2005), 1047–1051.
7. 7 Gao, X, Cassidy, A, Schwarzschild, MA, Rimm, EB, Ascherio, A, Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology 78 (2012), 1138–1145.
8. 8 Palacios, N, Fitzgerald, KC, Hart, JE, et al. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ Health, 13, 2014, 80.
9. 9 Palacios, N, Gao, X, O'Reilly, E, et al. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord 27 (2012), 980–987.
10. 10 Bornebroek, M, de Lau, LM, Haag, MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28 (2007), 193–196.
11. 11 Goldman, SM, Kamel, F, Ross, GW, et al. Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord 27 (2012), 1652–1658.
12. 12 Hu, G, Jousilahti, P, Bidel, S, Antikainen, R, Tuomilehto, J, Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007), 842–847.
13. 13 Sääksjärvi, K, Knekt, P, Männistö, S, et al. Reduced risk of Parkinson's disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol 29 (2014), 285–292.
14. 14 Dong, J, Beard, JD, Umbach, DM, et al. Dietary fat intake and risk for Parkinson's disease. Mov Disord 29 (2014), 1623–1630.
15. 15 Chen, H, Mosley, TH, Alonso, A, Huang, X, Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169 (2009), 1064–1069.
16. 16 Kyrozis, A, Ghika, A, Stathopoulos, P, Vassilopoulos, D, Trichopoulos, D, Trichopoulou, A, Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. Eur J Epidemiol 28 (2013), 67–77.
17. 17 Driver, JA, Logroscino, G, Lu, L, Gaziano, JM, Kurth, T, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ, 342, 2011, d198.
18. 18 Chen, H, Ding, D, Wang, J, et al. Parkinson's disease research in a prospective cohort in China. Parkinsonism Relat Disord 21 (2015), 1200–1204.
19. 19 Schrag, A, Horsfall, L, Walters, K, Noyce, A, Petersen, I, Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 14 (2015), 57–64.
20. 20 de Lau, LM, Breteler, MM, Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006), 525–535.
21. 21 Wirdefeldt, K, Adami, HO, Cole, P, Trichopoulos, D, Mandel, J, Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26:suppl 1 (2011), S1–58.
22. 22 Hirtz, D, Thurman, DJ, Gwinn-Hardy, K, Mohamed, M, Chaudhuri, AR, Zalutsky, R, How common are the “common” neurologic disorders?. Neurology 68 (2007), 326–337.
23. 23 Elbaz, A, Bower, JH, Maraganore, DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55 (2002), 25–31.
24. 24 Winkler, AS, Tütüncü, E, Trendafilova, A, et al. Parkinsonism in a population of northern Tanzania: a community-based door-to-door study in combination with a prospective hospital-based evaluation. J Neurol 257 (2010), 799–805.
25. 25 Dotchin, C, Msuya, O, Kissima, J, et al. The prevalence of Parkinson's disease in rural Tanzania. Mov Disord 23 (2008), 1567–1672.
26. 26 Okubadejo, NU, Bower, JH, Rocca, WA, Maraganore, DM, Parkinson's disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord 21 (2006), 2150–2156.
27. 27 Zhang, ZX, Roman, GC, Hong, Z, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365 (2005), 595–597.
28. 28 Tan, LC, Venketasubramanian, N, Jamora, RD, Heng, D, Incidence of Parkinson's disease in Singapore. Parkinsonism Relat Disord 13 (2007), 40–43.
29. 29 Mayeux, R, Marder, K, Cote, LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 142 (1995), 820–827.
30. 30 Van Den Eeden, SK, Tanner, CM, Bernstein, AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157 (2003), 1015–1022.
31. 31 Wright Willis, A, Evanoff, BA, Lian, M, Criswell, SR, Racette, BA, Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 34 (2010), 143–151.
32. 32 Horsfall, L, Petersen, I, Walters, K, Schrag, A, Time trends in incidence of Parkinson's disease diagnosis in UK primary care. J Neurol 260 (2013), 1351–1357.
33. 33 Darweesh, SK, Koudstaal, PJ, Stricker, BH, Hofman, A, Ikram, MA, Trends in the incidence of Parkinson disease in the general population: the rotterdam study. Am J Epidemiol 183 (2016), 1018–1026.
34. 34 Savica, R, Grossardt, BR, Bower, JH, Ahlskog, JE, Rocca, WA, Time trends in the incidence of Parkinson disease. JAMA Neurol 73 (2016), 981–989.
35. 35 Bower, JH, Maraganore, DM, McDonnell, SK, Rocca, WA, Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 15 (2000), 819–825.
36. 36 Taylor, KSM, Cook, JA, Counsell, CE, Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 78 (2007), 905–906.
37. 37 Chen, H, Zhang, SM, Hernán, MA, Willett, WC, Ascherio, A, Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol 52 (2002), 793–801.
38. 38 Chen, H, O'Reilly, E, McCullough, ML, et al. Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol 165 (2007), 998–1006.
39. 39 Sääksjärvi, K, Knekt, P, Lundqvist, A, et al. A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality. Br J Nutr 109 (2013), 329–337.
40. 40 Jiang, W, Ju, C, Jiang, H, Zhang, D, Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol 29 (2014), 613–619.
41. 41 Abbott, RD, Ross, GW, Petrovitch, H, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology 86 (2016), 512–519.
42. 42 Choi, HK, Atkinson, K, Karlson, EW, Willett, W, Curhan, G, Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350 (2004), 1093–1103.
43. 43 Langston, JW, Ballard, P, Tetrud, JW, Irwin, I, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983), 979–980.
44. 44 Petrovitch, H, Ross, GW, Abbott, RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 59 (2002), 1787–1792.
45. 45 Baldi, I, Cantagrel, A, Lebailly, P, et al. Association between Parkinson's disease and exposure to pesticides in southwestern France. Neuroepidemiology 22 (2003), 305–310.
46. 46 Ascherio, A, Chen, H, Weisskopf, MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60 (2006), 197–203.
47. 47 Weisskopf, MG, Knekt, P, O'Reilly, EJ, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology 74 (2010), 1055–1061.
48. 48 Tanner, CM, Kamel, F, Ross, GW, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119 (2011), 866–872.
49. 49 Guilarte, TR, Nihei, MK, McGlothan, JL, Howard, AS, Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122 (2003), 499–513.
50. 50 Callaghan, RC, Cunningham, JK, Sajeev, G, Kish, SJ, Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25 (2010), 2333–2339.
51. 51 Curtin, K, Fleckenstein, AE, Robison, RJ, Crookston, MJ, Smith, KR, Hanson, GR, Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend 146 (2015), 30–38.
52. 52 Liu, R, Gao, X, Lu, Y, Chen, H, Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76 (2011), 2002–2009.
53. 53 Olsen, JH, Friis, S, Frederiksen, K, Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17 (2006), 582–587.
54. 54 Wirdefeldt, K, Weibull, CE, Chen, H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol 179 (2014), 85–94.
55. 55 Constantinescu, R, Romer, M, Kieburtz, K, the DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 22 (2007), 720–722.
56. 56 Schwid, SR, Bausch, J, Oakes, D, et al., the PSG PRECEPT Investigators. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord 25 (2010), 1801–1808.
57. 57 Constantinescu, R, Elm, J, Auinger, P, et al., the NET-PD Investigators. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord 29 (2014), 263–265.
58. 58 Gao, X, Simon, KC, Han, J, Schwarzschild, MA, Ascherio, A, Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 65 (2009), 76–82.
59. 59 Gao, X, Simon, KC, Han, J, Schwarzschild, MA, Ascherio, A, Family history of melanoma and Parkinson disease risk. Neurology 73 (2009), 1286–1291.
60. 60 Lubbe, SJ, Escott-Price, V, Brice, A, et al., the International Parkinson's Disease Genomics Consortium. Is the MC1R variant p.R160W associated with Parkinson's?. Ann Neurol 79 (2016), 159–161.
61. 61 Meng, S, Song, F, Chen, H, et al. No association between Parkinson disease alleles and the risk of melanoma. Cancer Epidemiol Biomarkers Prev 21 (2012), 243–245.
62. 62 Song, F, Qureshi, AA, Gao, X, Li, T, Han, J, Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol 41 (2012), 1694–1705.
63. 63 Loftfield, E, Freedman, ND, Graubard, BI, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst, 107, 2015, 10.1093/jnci/dju421.
64. 64 Wu, S, Han, J, Song, F, et al. Caffeine intake, coffee consumption, and risk of cutaneous malignant melanoma. Epidemiology 26 (2015), 898–908.
65. 65 Wang, H, Chen, H, Gao, X, et al. Telomere length and risk of Parkinson's disease. Mov Disord 23 (2008), 302–305.
66. 66 Schürks, M, Buring, J, Dushkes, R, Gaziano, JM, Zee, RY, Kurth, T, Telomere length and Parkinson's disease in men: a nested case-control study. Eur J Neurol 21 (2014), 93–99.
67. 67 Bajaj, A, Driver, JA, Schernhammer, ES, Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21 (2010), 697–707.
68. 68 Marras, C, Hincapié, CA, Kristman, VL, et al. Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 95:suppl (2014), S238–S244.
69. 69 Rugbjerg, K, Ritz, B, Korbo, L, Martinussen, N, Olsen, JH, Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ, 337, 2008, a2494.
70. 70 Fang, F, Chen, H, Feldman, AL, Kamel, F, Ye, W, Wirdefeldt, K, Head injury and Parkinson's disease: a population-based study. Mov Disord 27 (2012), 1632–1635.
71. 71 Gardner, RC, Burke, JF, Nettiksimmons, J, Goldman, S, Tanner, CM, Yaffe, K, Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 77 (2015), 987–995.
72. 72 Abbott, RD, Ross, GW, White, LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 59 (2002), 1051–1057.
73. 73 Chen, H, Zhang, SM, Schwarzschild, MA, Hernán, MA, Willett, WC, Ascherio, A, Obesity and the risk of Parkinson's disease. Am J Epidemiol 159 (2004), 547–555.
74. 74 Hu, G, Jousilahti, P, Nissinen, A, Antikainen, R, Kivipelto, M, Tuomilehto, J, Body mass index and the risk of Parkinson disease. Neurology 67 (2006), 1955–1959.
75. 75 Logroscino, G, Sesso, HD, Paffenbarger, RS Jr, Lee, IM, Body mass index and risk of Parkinson's disease: a prospective cohort study. Am J Epidemiol 166 (2007), 1186–1190.
76. 76 Driver, JA, Smith, A, Buring, JE, Gaziano, JM, Kurth, T, Logroscino, G, Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31 (2008), 2003–2005.
77. 77 Palacios, N, Gao, X, McCullough, ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord 26 (2011), 2253–2259.
78. 78 Savica, R, Grossardt, BR, Ahlskog, JE, Rocca, WA, Metabolic markers or conditions preceding Parkinson's disease: a case-control study. Mov Disord 27 (2012), 974–979.
79. 79 Wang, YL, Wang, YT, Li, JF, Zhang, YZ, Yin, HL, Han, B, Body mass index and risk of Parkinson's disease: a dose-response meta-analysis of prospective studies. PLoS One, 10, 2015, e0131778.
80. 80 Sääksjärvi, K, Knekt, P, Männistö, S, Lyytinen, J, Heliövaara, M, Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease. Parkinsonism Relat Disord 21 (2015), 1148–1155.
81. 81 Schernhammer, E, Hansen, J, Rugbjerg, K, Wermuth, L, Ritz, B, Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34 (2011), 1102–1108.
82. 82 Sun, Y, Chang, YH, Chen, HF, Su, YH, Su, HF, Li, CY, Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35 (2012), 1047–1049.
83. 83 Xu, Q, Park, Y, Huang, X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 34 (2011), 910–915.
84. 84 Simon, KC, Chen, H, Schwarzschild, M, Ascherio, A, Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69 (2007), 1688–1695.
85. 85 Kim, SC, Liu, J, Solomon, DH, Risk of incident diabetes in patients with gout: a cohort study. Arthritis Rheum (Munch) 67 (2015), 273–280.
86. 86 Petersen, KF, Dufour, S, Befroy, D, Garcia, R, Shulman, GI, Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 (2004), 664–671.
87. 87 Aviles-Olmos, I, Limousin, P, Lees, A, Foltynie, T, Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136 (2013), 374–384.
88. 88 Santiago, JA, Potashkin, JA, Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med 19 (2013), 176–186.
89. 89 St-Pierre, J, Drori, S, Uldry, M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 (2006), 397–408.
90. 90 Wahlqvist, ML, Lee, MS, Hsu, CC, Chuang, SY, Lee, JT, Tsai, HN, Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 18 (2012), 753–758.
91. 91 Svenningsson, P, Wirdefeldt, K, Yin, L, et al. Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord, 2016, 10.1002/mds.2673.
92. 92 de Lau, LM, Koudstaal, PJ, Hofman, A, Breteler, MM, Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 164 (2006), 998–1002.
93. 93 Huang, X, Abbott, RD, Petrovitch, H, Mailman, RB, Ross, GW, Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 23 (2008), 1013–1018.
94. 94 Hu, G, Antikainen, R, Jousilahti, P, Kivipelto, M, Tuomilehto, J, Total cholesterol and the risk of Parkinson disease. Neurology 70 (2008), 1972–1979.
95. 95 Zhang, D, Jiang, H, Xie, J, Alcohol intake and risk of Parkinson's disease: a meta-analysis of observational studies. Mov Disord 29 (2014), 819–822.
96. 96 Yamamoto, T, Moriwaki, Y, Takahashi, S, Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 356 (2005), 35–57.
97. 97 Eriksson, AK, Löfving, S, Callaghan, RC, Allebeck, P, Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish national cohort study 1972-2008. BMC Neurol, 13, 2013, 190.
98. 98 Ascherio, A, Weisskopf, MG, O'Reilly, EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160 (2004), 977–984.
99. 99 Simon, KC, Chen, H, Gao, X, Schwarzschild, MA, Ascherio, A, Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 24 (2009), 1359–1365.
100. 100 Rugbjerg, K, Christensen, J, Tjønneland, A, Olsen, JH, Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 19 (2013), 457–460.
101. 101 Liu, R, Baird, D, Park, Y, et al. Female reproductive factors, menopausal hormone use, and Parkinson's disease. Mov Disord 29 (2014), 889–896.
102. 102 Wang, P, Li, J, Qiu, S, Wen, H, Du, J, Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies. Neuropsychiatr Dis Treat 11 (2015), 59–66.
103. 103 Ascherio, A, Chen, H, Schwarzschild, MA, Zhang, SM, Colditz, GA, Speizer, FE, Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003), 790–795.
104. 104 Palacios, N, Gao, X, McCullough, ML, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord 27 (2012), 1276–1282.
105. 105 Rocca, WA, Bower, JH, Maraganore, DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70 (2008), 200–209.
106. 106 Zhang, SM, Hernán, MA, Chen, H, Spiegelman, D, Willett, WC, Ascherio, A, Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59 (2002), 1161–1169.
107. 107 Chen, H, Zhang, SM, Schwarzschild, MA, et al. Folate intake and risk of Parkinson's disease. Am J Epidemiol 160 (2004), 368–375.
108. 108 de Lau, LM, Koudstaal, PJ, Witteman, JC, Hofman, A, Breteler, MM, Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67 (2006), 315–318.
109. 109 Knekt, P, Kilkkinen, A, Rissanen, H, Marniemi, J, Sääksjärvi, K, Heliövaara, M, Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67 (2010), 808–811.
110. 110 Ding, H, Dhima, K, Lockhart, KC, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology 81 (2013), 1531–1537.
111. 111 Dexter, DT, Wells, FR, Lees, AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52 (1989), 1830–1836.
112. 112 Logroscino, G, Chen, H, Wing, A, Ascherio, A, Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord 21 (2006), 835–838.
113. 113 Logroscino, G, Gao, X, Chen, H, Wing, A, Ascherio, A, Dietary iron intake and risk of Parkinson's disease. Am J Epidemiol 168 (2008), 1381–1388.
114. 114 Chen, H, Zhang, SM, Hernán, MA, Willett, WC, Ascherio, A, Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol 157 (2003), 1007–1014.
115. 115 de Lau, LM, Bornebroek, M, Witteman, JC, Hofman, A, Koudstaal, PJ, Breteler, MM, Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64 (2005), 2040–2045.
116. 116 Tan, LC, Koh, WP, Yuan, JM, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 167 (2008), 553–560.
117. 117 Abbott, RD, Ross, GW, White, LR, et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 250:suppl 3 (2003), III30–III39.
118. 118 Gardener, H, Gao, X, Chen, H, Schwarzschild, MA, Spiegelman, D, Ascherio, A, Prenatal and early life factors and risk of Parkinson's disease. Mov Disord 25 (2010), 1560–1567.
119. 119 Sasco, AJ, Paffenbarger, RS Jr, Measles infection and Parkinson's disease. Am J Epidemiol 122 (1985), 1017–1031.
120. 120 Fang, F, Wirdefeldt, K, Jacks, A, Kamel, F, Ye, W, Chen, H, CNS infections, sepsis and risk of Parkinson's disease. Int J Epidemiol 41 (2012), 1042–1049.
121. 121 Wu, WY, Kang, KH, Chen, SL, et al. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral Hepat 22 (2015), 784–791.
122. 122 Nielsen, HH, Qiu, J, Friis, S, Wermuth, L, Ritz, B, Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 19 (2012), 864–869.
123. 123 Racette, BA, Manganism in the 21st century: the Hanninen lecture. Neurotoxicology 45 (2014), 201–207.
124. 124 Li, X, Sundquist, J, Sundquist, K, Subsequent risks of Parkinson's disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis 10 (2012), 277–284.
125. 125 Yang, F, Johansson, AL, Pedersen, NL, Fang, F, Gatz, M, Wirdefeldt, K, Socioeconomic status in relation to Parkinson's disease risk and mortality: A population-based prospective study. Medicine (Baltimore), 95, 2016, e4337.
126. 126 Egeberg, A, Hansen, PR, Gislason, GH, Thyssen, JP, Exploring the association between rosacea and Parkinson disease: a danish nationwide cohort study. JAMA Neurol 73 (2016), 529–534.
127. 127 Goldman, SM, Quinlan, PJ, Ross, GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 71 (2012), 776–784.
128. 128 Klingelhoefer, L, Reichmann, H, Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. Nat Rev Neurol 11 (2015), 625–636.
129. 129 Morens, DM, Grandinetti, A, Reed, D, White, LR, Ross, GW, Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? [review]. Neurology 45 (1995), 1041–1051.
130. 130 Hernán, MA, Zhang, SM, Rueda-deCastro, AM, Colditz, GA, Speizer, FE, Ascherio, A, Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 50 (2001), 780–786.
131. 131 Thacker, EL, O'Reilly, EJ, Weisskopf, MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68 (2007), 764–768.
132. 132 Chen, H, Huang, X, Guo, X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 74 (2010), 878–884.
133. 133 O'Reilly, EJ, McCullough, ML, Chao, A, et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 20 (2005), 1383–1384.
134. 134 Tanner, CM, Goldman, SM, Aston, DA, et al. Smoking and Parkinson's disease in twins. Neurology 58 (2002), 581–588.
135. 135 Wirdefeldt, K, Gatz, M, Pawitan, Y, Pedersen, NL, Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 57 (2005), 27–33.
136. 136 Evans, AH, Lawrence, AD, Potts, J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006), 317–321.
137. 137 Sieurin, J, Gustavsson, P, Weibull, CE, et al. Personality traits and the risk for Parkinson disease: a prospective study. Eur J Epidemiol 31 (2016), 169–175.
138. 138 Ritz, B, Lee, PC, Lassen, CF, Arah, OA, Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 83 (2014), 1396–1402.
139. 139 Morozova, N, O'Reilly, EJ, Ascherio, A, Variations in gender ratios support the connection between smoking and Parkinson's disease. Mov Disord 23 (2008), 1414–1419.
140. 140 O'Reilly, EJ, Chen, H, Gardener, H, Gao, X, Schwarzschild, MA, Ascherio, A, Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. Am J Epidemiol 169 (2009), 678–682.
141. 141 Quik, M, O'Neill, M, Perez, XA, Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28 (2007), 229–235.
142. 142 Ross, GW, Abbott, RD, Petrovitch, H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000), 2674–2679.
143. 143 Liu, R, Guo, X, Park, Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 175 (2012), 1200–1207.
144. 144 Ascherio, A, Zhang, SM, Hernán, MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50 (2001), 56–63.
145. 145 Hu, G, Bidel, S, Jousilahti, P, Antikainen, R, Tuomilehto, J, Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 22 (2007), 2242–2248.
146. 146 Sääksjärvi, K, Knekt, P, Rissanen, H, Laaksonen, MA, Reunanen, A, Männistö, S, Prospective study of coffee consumption and risk of Parkinson's disease. Eur J Clin Nutr 62 (2008), 908–915.
147. 147 Kachroo, A, Irizarry, MC, Schwarzschild, MA, Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223 (2010), 657–661.
148. 148 Xu, K, Xu, YH, Chen, JF, Schwarzschild, MA, Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 167 (2010), 475–481.
149. 149 Xu, K, Xu, Y, Brown-Jermyn, D, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 26 (2006), 535–541.
150. 150 Trinh, K, Andrews, L, Krause, J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 30 (2010), 5525–5532.
151. 151 Lee, KW, Im, JY, Woo, JM, et al. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics 10 (2013), 143–153.
152. 152 Kitagawa, M, Houzen, H, Tashiro, K, Caffeine in Parkinson's disease: comment on its importance and the dose proposal. Mov Disord, 27, 2012, 808.
153. 153 Postuma, RB, Lang, AE, Munhoz, RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79 (2012), 651–658.
154. 154 Schwarzschild, MA, Caffeine in Parkinson disease: better for cruise control than snooze patrol?. Neurology 79 (2012), 616–618.
155. 155 Kondo, T, Mizuno, Y, the Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol 38 (2015), 41–46.
156. 156 Hauser, RA, Olanow, CW, Kieburtz, KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 13 (2014), 767–776.
157. 157 Lucas, M, Mirzaei, F, Pan, A, et al. Coffee, caffeine, and risk of depression among women. Arch Intern Med 171 (2011), 1571–1578.
158. 158 Levites, Y, Weinreb, O, Maor, G, Youdim, MB, Mandel, S, Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78 (2001), 1073–1082.
159. 159 Oda, M, Satta, Y, Takenaka, O, Takahata, N, Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19 (2002), 640–653.
160. 160 Duan, W, Ladenheim, B, Cutler, RG, Kruman, II, Cadet, JL, Mattson, MP, Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80 (2002), 101–110.
161. 161 Guerreiro, S, Ponceau, A, Toulorge, D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 109 (2009), 1118–1128.
162. 162 Gong, L, Zhang, QL, Zhang, N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway. J Neurochem 123 (2012), 876–885.
163. 163 Chen, X, Burdett, TC, Desjardins, CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci USA 110 (2013), 300–305.
164. 164 Bakshi, R, Zhang, H, Logan, R, et al. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis 82 (2015), 574–579.
165. 165 Davis, JW, Grandinetti, A, Waslien, CI, Ross, GW, White, LR, Morens, DM, Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144 (1996), 480–484.
166. 166 de Lau, LM, Koudstaal, PJ, Hofman, A, Breteler, MM, Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58 (2005), 797–800.
167. 167 Weisskopf, MG, O'Reilly, E, Chen, H, Schwarzschild, MA, Ascherio, A, Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 (2007), 561–567.
168. 168 O'Reilly, EJ, Gao, X, Weisskopf, MG, et al. Plasma urate and Parkinson's disease in women. Am J Epidemiol 172 (2010), 666–670.
169. 169 Jain, S, Ton, TG, Boudreau, RM, et al. The risk of Parkinson disease associated with urate in a community-based cohort of older adults. Neuroepidemiology 36 (2011), 223–229.
170. 170 Gao, X, O'Reilly, EJ, Schwarzschild, MA, Ascherio, A, Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86 (2016), 520–526.
171. 171 Alonso, A, Rodríguez, LA, Logroscino, G, Hernán, MA, Gout and risk of Parkinson disease: a prospective study. Neurology 69 (2007), 1696–1700.
172. 172 De Vera, M, Rahman, MM, Rankin, J, Kopec, J, Gao, X, Choi, H, Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 59 (2008), 1549–1554.
173. 173 Schernhammer, E, Qiu, J, Wermuth, L, Lassen, CF, Friis, S, Ritz, B, Gout and the risk of Parkinson's disease in Denmark. Eur J Epidemiol 28 (2013), 359–360.
174. 174 Reginato, AM, Mount, DB, Yang, I, Choi, HK, The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 8 (2012), 610–621.
175. 175 Facheris, MF, Hicks, AA, Minelli, C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 43 (2011), 246–250.
176. 176 González-Aramburu, I, Sánchez-Juan, P, Jesús, S, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 28 (2013), 1737–1740.
177. 177 Gao, J, Xu, H, Huang, X, Chen, H, Short communication: genetic variations of SLC2A9 in relation to Parkinson's disease. Transl Neurodegener, 2, 2013, 5.
178. 178 Gao, X, Chen, H, Choi, HK, Curhan, G, Schwarzschild, MA, Ascherio, A, Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 167 (2008), 831–838.
179. 179 Shoulson, I, the Parkinson Study Group (PSG) PRECEPT Investigators. CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study. Neurology, 67, 2006, 185 185b.
180. 180 Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993), 176–183.
181. 181 Schwarzschild, MA, Schwid, SR, Marek, K, et al., the Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65 (2008), 716–723.
182. 182 Ascherio, A, LeWitt, PA, Xu, K, et al., the Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66 (2009), 1460–1468.
183. 183 Simon, KC, Eberly, S, Gao, X, et al., the Parkinson Study Group. Mendelian randomization of serum urate and Parkinson disease progression. Ann Neurol 76 (2014), 862–868.
184. 184 Schwarzschild, MA, Ascherio, A, Beal, MF, et al., the Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 71 (2014), 141–150.
185. 185 Irizarry, MC, Raman, R, Schwarzschild, MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6 (2009), 23–28.
186. 186 Euser, SM, Hofman, A, Westendorp, RG, Breteler, MM, Serum uric acid and cognitive function and dementia. Brain 132 (2009), 377–382.
187. 187 Lu, N, Dubreuil, M, Zhang, Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 75 (2016), 547–551.
188. 188 Auinger, P, Kieburtz, K, McDermott, MP, The relationship between uric acid levels and Huntington's disease progression. Mov Disord 25 (2010), 224–228.
189. 189 Paganoni, S, Zhang, M, Quiroz Zárate, A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259 (2012), 1923–1928.
190. 190 Oh, SI, Baek, S, Park, JS, Piao, L, Oh, KW, Kim, SH, Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J Clin Neurol 11 (2015), 376–382.
191. 191 Chen, H, Zhang, SM, Schwarzschild, MA, Hernán, MA, Ascherio, A, Physical activity and the risk of Parkinson disease. Neurology 64 (2005), 664–669.
192. 192 Logroscino, G, Sesso, HD, Paffenbarger, RS Jr, Lee, IM, Physical activity and risk of Parkinson's disease: a prospective cohort study. J Neurol Neurosurg Psychiatry 77 (2006), 1318–1322.
193. 193 Thacker, EL, Chen, H, Patel, AV, et al. Recreational physical activity and risk of Parkinson's disease. Mov Disord 23 (2008), 69–74.
194. 194 Xu, Q, Park, Y, Huang, X, et al. Physical activities and future risk of Parkinson disease. Neurology 75 (2010), 341–348.
195. 195 Yang, F, Trolle Lagerros, Y, Bellocco, R, et al. Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 138 (2015), 269–275.
196. 196 Cohen, AD, Tillerson, JL, Smith, AD, Schallert, T, Zigmond, MJ, Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85 (2003), 299–305.
197. 197 Zigmond, MJ, Smeyne, RJ, Exercise: is it a neuroprotective and if so, how does it work?. Parkinsonism Relat Disord 20:suppl 1 (2014), S123–S127.
198. 198 Hirsch, MA, Iyer, SS, Sanjak, M, Exercise-induced neuroplasticity in human Parkinson's disease: what is the evidence telling us?. Parkinsonism Relat Disord 22:suppl 1 (2016), S78–S81.
199. 199 van Nimwegen, M, Speelman, AD, Overeem, S, et al., the ParkFit Study Group. Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. BMJ, 346, 2013, f576.
200. 200 Hirsch, EC, Hunot, S, Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 8 (2009), 382–397.
201. 201 Chen, H, Zhang, SM, Hernán, MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003), 1059–1064.
202. 202 Chen, H, Jacobs, E, Schwarzschild, MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58 (2005), 963–967.
203. 203 Gao, X, Chen, H, Schwarzschild, MA, Ascherio, A, Use of ibuprofen and risk of Parkinson disease. Neurology 76 (2011), 863–869.
204. 204 Hernán, MA, Logroscino, G, García Rodríguez, LA, Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006), 1097–1099.
205. 205 Ton, TG, Heckbert, SR, Longstreth, WT Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 21 (2006), 964–969.
206. 206 Bower, JH, Maraganore, DM, Peterson, BJ, Ahlskog, JE, Rocca, WA, Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67 (2006), 494–496.
207. 207 Becker, C, Jick, SS, Meier, CR, NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol 18 (2011), 1336–1342.
208. 208 Asanuma, M, Miyazaki, I, Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des 14 (2008), 1428–1434.
209. 209 Asanuma, M, Miyazaki, I, Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?. Exp Neurol 206 (2007), 172–178.
210. 210 Tsuji, T, Asanuma, M, Miyazaki, I, Miyoshi, K, Ogawa, N, Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 34 (2009), 764–774.
211. 211 Vlad, SC, Miller, DR, Kowall, NW, Felson, DT, Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70 (2008), 1672–1677.
212. 212 Helmuth, L, NSAIDS for prevention? Protecting the brain while killing pain?. Science 297 (2002), 1262–1263.
213. 213 Becker, C, Jick, SS, Meier, CR, Use of antihypertensives and the risk of Parkinson disease. Neurology 70 (2008), 1438–1444.
214. 214 Ritz, B, Rhodes, SL, Qian, L, Schernhammer, E, Olsen, JH, Friis, S, L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67 (2010), 600–606.
215. 215 Pasternak, B, Svanström, H, Nielsen, NM, Fugger, L, Melbye, M, Hviid, A, Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 175 (2012), 627–635.
216. 216 Lee, YC, Lin, CH, Wu, RM, Lin, JW, Chang, CH, Lai, MS, Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS One, 9, 2014, e98961.
217. 217 Simon, KC, Gao, X, Chen, H, Schwarzschild, MA, Ascherio, A, Calcium channel blocker use and risk of Parkinson's disease. Mov Disord 25 (2010), 1818–1822.
218. 218 Ton, TG, Heckbert, SR, Longstreth, WT Jr, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord 13 (2007), 165–169.
219. 219 Surmeier, DJ, Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 6 (2007), 933–938.
220. 220 Human, JA, Ubbink, JB, Jerling, JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 263 (1997), 67–77.
221. 221 Mortensen, SA, Leth, A, Agner, E, Rohde, M, Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 18:suppl (1997), S137–S144.
222. 222 De Pinieux, G, Chariot, P, Ammi-Saïd, M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42 (1996), 333–337.
223. 223 Shults, CW, Oakes, D, Kieburtz, K, et al., the Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002), 1541–1550.
224. 224 Beal, MF, Oakes, D, Shoulson, I, et al., the Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71 (2014), 543–552.
225. 225 Becker, C, Jick, SS, Meier, CR, Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 31 (2008), 399–407.
226. 226 de Lau, LM, Stricker, BH, Breteler, MM, Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord, 22, 2007, 1985.
227. 227 Samii, A, Carleton, BC, Etminan, M, Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 15 (2008), 1272–1273.
228. 228 Ritz, B, Manthripragada, AD, Qian, L, et al. Statin use and Parkinson's disease in Denmark. Mov Disord 25 (2010), 1210–1216.
229. 229 Wolozin, B, Wang, SW, Li, NC, Lee, A, Lee, TA, Kazis, LE, Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med, 5, 2007, 20.
230. 230 Gao, X, Simon, KC, Schwarzschild, MA, Ascherio, A, Age, statin use, and the risk for incident Parkinson disease—reply. Arch Neurol, 69, 2012, 1381.
231. 231 Undela, K, Gudala, K, Malla, S, Bansal, D, Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 260 (2013), 158–165.
232. 232 Lin, KD, Yang, CY, Lee, MY, Ho, SC, Liu, CK, Shin, SJ, Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol, 2016, 10.1002/ana.24751.
233. 233 Huang, X, Alonso, A, Guo, X, et al. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord 30 (2015), 552–559.
234. 234 Gao, X, Chen, H, Fung, TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 86 (2007), 1486–1494.
235. 235 Chomistek, AK, Cook, NR, Flint, AJ, Rimm, EB, Vigorous-intensity leisure-time physical activity and risk of major chronic disease in men. Med Sci Sports Exerc 44 (2012), 1898–1905.
236. 236 Je, Y, Giovannucci, E, Coffee consumption and total mortality: a meta-analysis of twenty prospective cohort studies. Br J Nutr 111 (2014), 1162–1173.
237. 237 Noyce, AJ, Lees, AJ, Schrag, AE, The prediagnostic phase of Parkinson's disease. J Neurol Neurosurg Psychiatry 87 (2016), 871–878.
238. 238 Ravina, BM, Fagan, SC, Hart, RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003), 1234–1240.